Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Beglinger C, Hu K, Wang Y, Bouillaud E, Darstein C, Wang Y, Mohideen P

Endocrine21 Apr 2012Cited by 15 (Europe PMC)

PMID22527887DOI10.1007/s12020-012-9668-1PepBankPUB-22527887

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

01HumanRandomized controlled trialSafety outcome
In healthy men, pasireotide 600 μg sc was associated with higher preprandial glucose than placebo.
In plain wordsIn healthy men, pasireotide 600 μg was linked to higher blood sugar before meals than placebo.
Peptide
Pasireotide
Outcome
IncreasePreprandial glucose versus placebo
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Pasireotide 600 μg sc was associated with pre- and post-prandial elevations in glucose levels relative to placebo; however, this effect was less pronounced on day 14 compared with day 1.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788704
02HumanRandomized controlled trialSafety outcome
In healthy men, pasireotide 600 μg sc was associated with higher postprandial glucose than placebo.
In plain wordsIn healthy men, pasireotide 600 μg was linked to higher blood sugar after meals than placebo.
Peptide
Pasireotide
Outcome
IncreasePostprandial glucose versus placebo
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Pasireotide 600 μg sc was associated with pre- and post-prandial elevations in glucose levels relative to placebo; however, this effect was less pronounced on day 14 compared with day 1.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788705
03HumanNon-randomized trialSafety outcome
In healthy men receiving pasireotide, 18 reported drug-related injection-site reactions, mostly mild or moderate.
In plain wordsIn healthy men receiving pasireotide, 18 reported injection-site reactions, mostly mild or moderate.
Peptide
Pasireotide
Outcome
Not applicableInjection-site reactions
Study
n: not reported in source
Outcome group
Adverse events · Skin and wound
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Participants with drug-related injection-site reactions
18 participants
pasireotide 50, 200 or 600 μg sc qd for 14 days
Source sentences
Summary
The most frequently reported drug-related adverse events were injection-site reactions (n = 18), diarrhea (n = 14) and nausea (n = 10), which were mostly mild or moderate in intensity.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788701
04HumanNon-randomized trialSafety outcome
In healthy men receiving pasireotide, 14 reported drug-related diarrhea, mostly mild or moderate.
In plain wordsIn healthy men receiving pasireotide, 14 reported diarrhea, mostly mild or moderate.
Peptide
Pasireotide
Outcome
Not applicableDiarrhea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Participants with drug-related diarrhea
14 participants
pasireotide 50, 200 or 600 μg sc qd for 14 days
Source sentences
Summary
The most frequently reported drug-related adverse events were injection-site reactions (n = 18), diarrhea (n = 14) and nausea (n = 10), which were mostly mild or moderate in intensity.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788702
05HumanNon-randomized trialSafety outcome
In healthy men receiving pasireotide, 10 reported drug-related nausea, mostly mild or moderate.
In plain wordsIn healthy men receiving pasireotide, 10 reported nausea, mostly mild or moderate.
Peptide
Pasireotide
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Participants with drug-related nausea
10 participants
pasireotide 50, 200 or 600 μg sc qd for 14 days
Source sentences
Summary
The most frequently reported drug-related adverse events were injection-site reactions (n = 18), diarrhea (n = 14) and nausea (n = 10), which were mostly mild or moderate in intensity.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788703
06HumanNon-randomized trialSafety outcome
In healthy men receiving pasireotide 600 μg, glucose elevations were less pronounced on day 14 than day 1.
In plain wordsIn healthy men, pasireotide-related blood sugar elevations were smaller on day 14 than day 1.
Peptide
Pasireotide
Outcome
DecreaseGlucose effect attenuation
Study
n: not reported in source
Comparator
day 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Pasireotide 600 μg sc was associated with pre- and post-prandial elevations in glucose levels relative to placebo; however, this effect was less pronounced on day 14 compared with day 1.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788706
07HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide appeared to reach PK steady state after 3 days of dosing.
In plain wordsIn healthy men, pasireotide appeared to reach stable exposure after three days of dosing.
Peptide
Pasireotide
Outcome
Not applicableTime to steady state
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Time to PK steady state
3 days
pasireotide sc qd, healthy men
Source sentences
Summary
PK steady state appeared to be achieved after 3 days of dosing and PK exposures had a moderate accumulation of 20-40 % across doses.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788707
08HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide PK exposure accumulated by 20-40 % across doses.
In plain wordsIn healthy men, repeated pasireotide dosing increased exposure by 20-40 %.
Peptide
Pasireotide
Outcome
IncreaseAccumulation
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Accumulation
20 to 40%
pasireotide sc qd across doses
Source sentences
Summary
PK steady state appeared to be achieved after 3 days of dosing and PK exposures had a moderate accumulation of 20-40 % across doses.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788708
09HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide steady-state T(max,ss) was 0.25-0.5 h.
In plain wordsIn healthy men, pasireotide reached peak levels in 0.25-0.5 h at steady state.
Peptide
Pasireotide
Outcome
Not applicableAbsorption time
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Tmax,ss
0.25 to 0.5 h
pasireotide sc qd steady state
Source sentences
Summary
Pasireotide demonstrated fast absorption (T(max,ss): 0.25-0.5 h)
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788709
10HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide steady-state CL/F(ss) was 8.10-9.03 L/h.
In plain wordsIn healthy men, pasireotide clearance was 8.10-9.03 L/h at steady state.
Peptide
Pasireotide
Outcome
Not applicableClearance
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
CL/F(ss)
8.1 to 9.03 L/h
pasireotide sc qd steady state
Source sentences
Summary
low clearance (CL/F(ss): 8.10-9.03 L/h)
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788710
11HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide effective half-life averaged approximately 12 h, ranging from 9.7 to 13.1 h across doses.
In plain wordsIn healthy men, pasireotide effective half-life averaged about 12 hours.
Peptide
Pasireotide
Outcome
Not applicableEffective half-life
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Effective half-life (mean)
≈ 12 h
pasireotide sc qd
Effective half-life, mean by dose
9.7 to 13.1 h
50, 200 and 600 μg sc qd
Source sentences
Summary
long effective half-life (T(½,eff): ~12 h, on average between 9.7 and 13.1 h for 50, 200, and 600 μg sc qd)
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788711
12HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide steady-state V(z)/F(ss) was 251-1,091 L.
In plain wordsIn healthy men, pasireotide distribution volume was 251-1,091 L at steady state.
Peptide
Pasireotide
Outcome
Not applicableDistribution volume
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Measurements
Vz/F(ss)
251 to 1091 L
pasireotide sc qd steady state
Source sentences
Summary
and large volume of distribution (V(z)/F(ss): 251-1,091 L) at steady state.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788712
13HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide C(max,ss) was dose proportional.
In plain wordsIn healthy men, pasireotide peak steady-state concentration increased in proportion to dose.
Peptide
Pasireotide
Outcome
IncreaseC(max,ss) dose proportionality
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Dose proportionality was confirmed for C(max,ss); other PK parameters (C(max), AUC(0-24 h) and AUC(tau)) were approximately dose proportional.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788713
14HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide C(max) was approximately dose proportional.
In plain wordsIn healthy men, pasireotide peak concentration increased approximately in proportion to dose.
Peptide
Pasireotide
Outcome
IncreaseC(max) dose proportionality
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Dose proportionality was confirmed for C(max,ss); other PK parameters (C(max), AUC(0-24 h) and AUC(tau)) were approximately dose proportional.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788714
15HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide AUC(0-24 h) was approximately dose proportional.
In plain wordsIn healthy men, pasireotide daily exposure increased approximately in proportion to dose.
Peptide
Pasireotide
Outcome
IncreaseAUC(0-24 h) dose proportionality
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Dose proportionality was confirmed for C(max,ss); other PK parameters (C(max), AUC(0-24 h) and AUC(tau)) were approximately dose proportional.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788715
16HumanNon-randomized trialPharmacokinetics
In healthy men, pasireotide AUC(tau) was approximately dose proportional.
In plain wordsIn healthy men, pasireotide exposure over the dosing interval increased approximately in proportion to dose.
Peptide
Pasireotide
Outcome
IncreaseAUC(tau) dose proportionality
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
50, 200, or 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Dose proportionality was confirmed for C(max,ss); other PK parameters (C(max), AUC(0-24 h) and AUC(tau)) were approximately dose proportional.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788716
17HumanNon-randomized trialMechanism
In healthy men, pasireotide 200 and 600 μg inhibited growth hormone.
In plain wordsIn healthy men, pasireotide 200 and 600 μg suppressed growth hormone.
Peptide
Pasireotide
Outcome
DecreaseGrowth hormone inhibition
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
200 and 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Growth hormone inhibition was observed with pasireotide 200 and 600 μg sc qd.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788717
18HumanNon-randomized trialMechanism
In healthy men, postprandial gallbladder volume increased with pasireotide 200 and 600 μg.
In plain wordsIn healthy men, gallbladder volume after meals increased with pasireotide 200 and 600 μg.
Peptide
Pasireotide
Outcome
IncreasePostprandial gallbladder volume
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
200 and 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Gallbladder volume increased post-prandially with pasireotide 200 and 600 μg sc qd, which appeared to correlate with reduced levels of cholecystokinin at these doses.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788718
19HumanNon-randomized trialMechanism
In healthy men, cholecystokinin levels decreased with pasireotide 200 and 600 μg.
In plain wordsIn healthy men, cholecystokinin levels decreased with pasireotide 200 and 600 μg.
Peptide
Pasireotide
Outcome
DecreaseCholecystokinin levels
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
200 and 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Gallbladder volume increased post-prandially with pasireotide 200 and 600 μg sc qd, which appeared to correlate with reduced levels of cholecystokinin at these doses.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788719
20HumanObservational studyOther
In healthy men receiving pasireotide, increased postprandial gallbladder volume appeared to correlate with reduced cholecystokinin at 200 and 600 μg.
In plain wordsIn healthy men receiving pasireotide, larger gallbladder volume after meals appeared linked to lower cholecystokinin.
Peptide
Pasireotide
Outcome
MixedGallbladder volume and cholecystokinin association
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
200 and 600 μg once daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
Gallbladder volume increased post-prandially with pasireotide 200 and 600 μg sc qd, which appeared to correlate with reduced levels of cholecystokinin at these doses.
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects.
Summary · context
Subjects received pasireotide 50, 200, or 600 μg sc qd for 14 days and placebo in separate sequences.
Report a problemFND-2252788720

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Summary

Results from this study20

Version history

Subjects

Publication types

MeSH terms